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Abstract: Limb-girdle muscular dystrophy recessive 1 (LGMDR1), previously known as LGMD2A,
is a rare disease caused by mutations in the CAPN3 gene. It is characterized by progressive
weakness of shoulder, pelvic, and proximal limb muscles that usually appears in children and
young adults and results in loss of ambulation within 20 years after disease onset in most patients.
The pathophysiological mechanisms involved in LGMDR1 remain mostly unknown, and to date,
there is no effective treatment for this disease. Here, we review clinical and experimental evidence
suggesting that dysregulation of Ca2+ homeostasis in the skeletal muscle is a significant underlying
event in this muscular dystrophy. We also review and discuss specific clinical features of LGMDR1,
CAPN3 functions, novel putative targets for therapeutic strategies, and current approaches aiming to
treat LGMDR1. These novel approaches may be clinically relevant not only for LGMDR1 but also for
other muscular dystrophies with secondary calpainopathy or with abnormal Ca2+ homeostasis, such
as LGMD2B/LGMDR2 or sporadic inclusion body myositis.
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1. Overview of Calcium Homeostasis in the Skeletal Muscle
Ca2+ plays a vital role in a wide range of cellular processes such as gene transcription, membrane
resealing, secretion, neurotransmission, as well as cell differentiation, proliferation, or survival [1,2].
In skeletal muscle fibers, Ca2+ is crucial for both electric activation along the motor endplate and
skeletal muscle contraction. In addition, Ca2+ is involved in many other functions such as protein
synthesis, protein degradation, fiber type shifting, Ca2+-regulated proteolysis, transcription factor
modulation, mitochondrial adaptation, cell plasticity, and respiration [3]. Therefore, tight regulation of
Ca2+ levels is essential for the proper function of skeletal muscle (Figure 1).
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Figure 1. Representation of Ca2+ fluxes in the muscle fiber. Upon sarcolemmal depolarization reaching 
T-tubules (1), DHPRs undergo a conformational change that activates RyR1 channels and results in 
Ca2+ release from the SR (2). Ca2+ diffuses to the sarcomere where it initiates muscle contraction (3). 
Muscle relaxation takes place when Ca2+ is sequestered into the SR by SERCAs (4) or pumped out of 
the fiber by membrane channels (NCX, PMCA) (5). Cytosolic Ca2+ also binds CaM, which activates 
the Ca2+-dependent signaling pathways resulting in muscle gene regulation (6). Cytosolic Ca2+ also 
reaches mitochondria (7), where it stimulates metabolism and ATP synthesis required for muscle 
contraction and relaxation. 
1.1. Ca2+ in Excitation-Contraction Coupling 
Muscle contraction initiates by depolarization of the sarcolemma in response to acetylcholine 
release from motoneurons. The action potential propagates into the triads, which are anatomical 
structures formed by the association of sarcolemmal transverse tubules (T-tubules) and sarcoplasmic 
reticulum (SR) terminal cisternae [4]. Triads play an essential role in excitation-contraction coupling 
(ECC) since they allow close contact and synchronization between crucial receptors in the 
sarcolemma and the SR. See [3,5] for review. Membrane depolarization activates dihydropyridine 
receptors (DHPRs) in the T-tubules [6], and this results in activation of the closely apposed ryanodine 
receptors (RyRs), the main Ca2+ release channels in the SR [7]. RyR1, the predominant RyR isoform in 
skeletal muscle, releases Ca2+ from the SR into the cytosol either after activation by DHPRs or 
increased cytosolic Ca2+ levels [8]. RyR1 function is modulated by post-translational modifications, 
such as S-nitrosylation, S-glutathionylation, and phosphorylation by both Protein Kinase A (PKA) 
and Ca2+/calmodulin-dependent protein kinase II (CaMKII) [9]. RyRs operate in coordination with 
other proteins in order to maintain the balance between Ca2+ release, Ca2+ storage, and Ca2+ reuptake 
[10]. Indeed, a variety of proteins and small molecules, both in the SR lumen and cytosol are needed 
for this tight coordination [9]. On the cytosolic side, calmodulin (CaM), a Ca2+ sensor, has a dual effect 
on RyR1, functioning as an activator at low cytosolic Ca2+ levels and as an inhibitor at high cytosolic 
Ca2+ levels [11]. On the SR luminal side, calsequestrin (CSQ) forms a complex with RyRs, junctin, and 
triadin. RyR function is inhibited by the binding of CSQ, which essentially depends on luminal Ca2+ 
concentration [12]. CSQ is the main Ca2+-binding protein in the SR lumen, and it functions as an 
endogenous regulator of Ca2+ fluxes and as a Ca2+ reservoir with a moderate affinity but high capacity 
Figure 1. Representation of Ca2+ fl es i t e uscle fiber. Upon sarcole mal depolarization reaching
T-tubules (1), DHPRs undergo a conformational change that activates RyR1 channels and results in
Ca2+ release from the SR (2). Ca2+ diffuses to the sarcomere where it initiates muscle contraction (3).
Muscle relaxation takes place when Ca2+ is sequestered into the SR by SERCAs (4) or pumped out of
the fiber by membrane channels (NCX, PMCA) (5). Cytosolic Ca2+ also binds CaM, which activates the
Ca2+-dependent signaling pathways resulting in muscle gene regulation (6). Cytosolic Ca2+ also reaches
mitochondria (7), where it stimulates metabolism and ATP synthesis required for muscle contraction
and relaxation.
1.1. Ca2+ in Excitation-Contraction Coupling
Muscle contraction initiates by depolarization of the sarcolemma in response to acetylcholine
release from motoneurons. The action potential propagates into the triads, which are anatomical
structures formed by the association of sarcolemmal transverse tubules (T-tubules) and sarcoplasmic
reticulum (SR) terminal cisternae [4]. Triads play an essential role in excitation-contraction coupling
(ECC) since they allow close contact and synchronization between crucial receptors in the sarcolemma
and the SR. See [3,5] for review. Membrane depolarization activates dihydropyridine receptors
(DHPRs) in the T-tubules [6], and this results in activation of the closely apposed ryanodine receptors
(RyRs), the ain Ca2+ release channels in the SR [7]. RyR1, the predominant RyR isoform in skeletal
muscle, releases Ca2+ from the SR into the cytosol either after activatio by DHPRs or increased
cytosolic Ca2+ levels [8]. RyR1 function is modulated b post-translational modifications, such
as S-nitrosyl tion, S-glutathionylati n, and phosphorylation by both Protein Kinase A (PKA) and
Ca2+/calm dulin-dependent protei kinase II (CaMKII) [9]. RyRs operate in coordination with other
proteins in or er to maintain the balance between Ca2+ release, Ca2+ storage, and Ca2+ reuptak [10].
Indeed, a variety of proteins and small molecules, both in the SR lumen and cytosol are needed for
this tight coordination [9]. On the cytosolic side, calmodulin (CaM), a Ca2+ sensor, has a dual effect
on RyR1, functioning as an activator at low cytosolic Ca2+ levels and as an inhibitor at high cytosolic
Ca2+ levels [11]. On the SR luminal side, calsequestrin (CSQ) forms a complex with RyRs, junctin,
and triadin. RyR function is inhibited by the binding of CSQ, which essentially depends on luminal
Ca2+ concentration [12]. CSQ is the main Ca2+-binding protein in the SR lumen, and it functions as an
endogenous regulator of Ca2+ fluxes and as a Ca2+ reservoir with a moderate affinity but high capacity
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to bind Ca2+ [13]. After Ca2+ release into the cytosol through RyR1, Ca2+ binds to various cytosolic
Ca2+ buffers, such as ATP and CaM, and it can also be sequestered by mitochondria. At the sarcomere,
the contractile unit of the skeletal muscle, troponin C undergoes a Ca2+-dependent conformational
change that ultimately results in myosin and actin cross-bridge cycling and muscle contraction [14].
Upon muscle excitation, cytosolic Ca2+ levels raise from ~100 nM (resting levels) to ~10µM in slow
fibers, and ~18 µM in fast fibers [15].
Muscle relaxation initiates by lowering of cytosolic Ca2+ back to resting levels, which mainly relies
on sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pumps [16], and sarcolemmal Ca2+ transporters
such as Na+/Ca2+ exchangers (NCX1-3) and the plasma membrane Ca2+-ATPase (PMCA) [3]. SERCA
actively transports Ca2+ from the cytosol into the SR against a large concentration gradient at the
expense of ATP hydrolysis. Fast muscle fibers express SERCA1a isoform, whereas slow fibers and
cardiac muscle express SERCA2a isoform [16]. Since SERCA pumps are major ATP consumers, they are
strongly affected by changes in cell energetics and ATP supply [17]. Similarly to RyRs, SERCAs are also
modulated by several cytosolic and SR luminal proteins, as well as by post-translational modifications,
including N-glycosylation, S-glutathionylation, and phosphorylation [18], although there is some
controversy over SERCA modulation through phosphorylation. Also, the short integral membrane
proteins phospholamban (PLN) and sarcolipin (SLN) inhibit SERCA activity [19]. Phosphorylation
of PLN by PKA or CaMKII results in SERCA activation through dissociation of PLN from the Ca2+
pump [18].
1.2. Ca2+-Mediated Signaling Pathways
In addition to its role in ECC, Ca2+ is also a key regulator of gene transcription triggered by
different stimuli. For instance, intracellular Ca2+ signals mediate transcriptional changes necessary
for skeletal muscle adaptation in response to changes in activation patterns [20]. CaMK pathway and
Calcineurin (Cn), a Ca2+/CaM-dependent serine/threonine protein phosphatase, have crucial roles
in many of these Ca2+-mediated signaling processes. Cn stimulates the transcription of both NFAT
and NF-κB targeted genes [21,22]. While the Cn/NFAT pathway responds preferentially to sustained
and low-amplitude elevations of intracellular Ca2+, high amplitude oscillations activate NF-κB [23].
NFAT signaling induces the slow gene program during muscle regeneration and maintains the slow
fiber phenotype in the adult muscle tissue, whereas NF-κB regulates the gene program for myoblast
proliferation and differentiation [24,25]. Interestingly, depending on the stimulus nature, NF-κB can
behave either as a promoter or antagonist of apoptosis [26].
CaMK pathway is involved in the regulation of contraction-induced Ca2+ handling, and
mitochondrial biogenesis. It also regulates gene expression in skeletal muscle, promoting the slow
to fast fiber shift [27]. Also, during muscle development and adaptation, CaMK activates critical
transcription factors such as MEF2 (myocyte enhancer factor 2) via phosphorylation of class II histone
deacetylases (HDACs) [28]. CaMKII, the main CaMK in the skeletal muscle, is involved in the
maintenance of myofiber phenotype and muscle growth [29,30]. In addition, CaMKII is one of the
upstream activators of AMP-activated protein kinase (AMPK), an energy sensor that coordinates
cell growth and autophagy, as well as regulates mitochondrial function and biogenesis. Under low
intracellular ATP levels, AMPK promotes catabolic pathways to generate more ATP and suppresses
anabolic pathways such as the high ATP consuming mTORC1 pathway, to inhibit cell growth [31].
1.3. Ca2+ in Mitochondria
Mitochondria are, together with SR, main Ca2+ storages, and they also function as a source of
intracellular Ca2+ [2]. They account for about 15% of the cytosolic volume in oxidative fibers [32],
and they are located close to the SR in the skeletal muscle. There is a significant interplay between
mitochondria and SR through the mitochondria-associated SR membrane (MAM), which is essential
for cell physiology and Ca2+ homeostasis [33]. Ca2+ regulates mitochondrial metabolism, biogenesis,
motility, distribution, and plasticity [34–36]. In turn, mitochondria can also affect intracellular Ca2+
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levels. Thus, ECC triggers transient Ca2+ increases in the mitochondrial matrix, which are essential
to promote mitochondrial metabolism and ATP synthesis. This is required to balance the ATP
consumption of actomyosin cross-bridge cycling and SERCA pumps during contraction and relaxation,
respectively [37]. Alternatively, Ca2+ overload in the mitochondria may induce the opening of
permeability transient pores (PTP) that results in a massive release of Ca2+ and pro-apoptotic factors
such as cytochrome C (Cyt-c) into the cytosol, which, in turn, activate caspase 9 and initiate the
apoptotic program [38,39].
Ca2+ is also involved in mitochondrial biogenesis through regulation of the CaMKII pathway.
Indeed, the expression of peroxisome proliferator-activated receptor gamma coactivator 1 alpha
(PGC1α), a key regulator of mitochondrial biogenesis, depends on the Ca2+-mediated activation of
CaMKII [40]. Finally, mitochondrial motility also relies on cytosolic [Ca2+]. Indeed, myosin-Va, a
Ca2+ sensor molecule, may regulate mitochondria-bound molecular motors allowing mitochondrial
movements along cytoskeletal fibers and controlling the distribution of mitochondria to enhance Ca2+
buffering and ATP production in regions with high cytosolic [Ca2+] [36].
2. Limb-Girdle Muscular Dystrophy-Recessive 1
LGMDR1, also known as calpainopathy and previously symbolized LGMD2A [41], is caused by
homozygous or compound heterozygous mutation in the CAPN3 gene encoding for the proteolytic
enzyme calpain 3 (CAPN3) [42]. Recently, heterozygous mutations in the CAPN3 gene have been
reported to cause autosomal dominant limb-girdle muscular dystrophy-4 (LGMDD4), with a later
onset and milder phenotype [43–45], although the mechanisms underlying these cases still need some
clarification [46]. The prevalence of LGMDR1 ranges from 1 to 9 cases per 100,000 people, and it
represents almost 30% of all LGMD cases in open populations [47–53] with some ancestral mutations
responsible for specific ethnic or geographic clusters [54–58]. By September 2019, there are more than
480 pathogenic variants of CAPN3 reported in the Leiden Open Variation database [59]. The molecular
spectrum covers all CAPN3 exons with some hot regions related to severe or benign phenotypes, as
well as intronic variants [51,60].
LGMDR1 is characterized by progressive muscle weakness and degeneration, with a predominant
effect on shoulder, pelvic, and proximal limb muscles [61]. There is no affection of cardiac and facial
muscles, and no cognitive defects have been reported in this disease [47]. Age of onset is highly
variable, although initial symptoms usually appear between eight and 15 years [62] and patients loss
ambulation around 10 to 20 years after the onset [54,55]. However, lately, benign forms are being
increasingly reported with preserved ambulation even after reaching 60 or more years old. In general,
these benign forms have metabolic symptoms at onset (myalgia, cramps, and exercise intolerance) or
even asymptomatic hyper-creatine kinase-emia that may carry on for years before muscle weakness.
Symptoms of the classical LGMDR1 phenotype fit with the criteria described by Erb in 1884 to define
juvenile muscular dystrophy [54]. However, there is certain variability regarding disease progression
and severity related to gender, as well as the type and localization of mutations [51]. Moreover,
a phenomenon known as de novo intermolecular complementation (iMOC) of CAPN3 may also
lead to a milder phenotype in compound heterozygotes [63]. Additionally, in some families, there
is considerable phenotypic variability among patients with identical mutations [64], which makes
prognosis in LGMDR1 very challenging [47].
Since the discovery of CAPN3 as the gene responsible for LGMDR1, several groups have been
trying to identify the pathogenic mechanisms that may give rise to the clinical and histological features
of LGMDR1. Although to date, these mechanisms are not entirely understood, there is solid evidence
indicating that CAPN3 is a multifunctional protein. Different studies performed in animal models and
human samples have shown that CAPN3 deficiency is associated with different features in the skeletal
muscle such as oxidative damage [65,66], Ca2+ dysregulation [67,68], sarcomere disorganization [69],
mitochondrial abnormalities [66,70–72], abnormal muscle adaptation [73,74], and impaired muscle
regeneration [71], which together would lead to inflammation, necrosis, fibrosis, atrophy, and progressive
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muscle degeneration, characteristic of LGMDR1 (Figures 2 and 3). Indeed, patients in the early stages
of the disease present an increased concentration of serum creatine kinase (CK), which is an unspecific
hallmark of muscle damage [55,75]. Some patients at this stage present eosinophilic infiltrations associated
with peripheral blood eosinophilia that have an unclear pathogenic significance [50,54,76]. Fibrosis is
often present, and it tends to increase with disease progression [75].
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Muscle biopsies from LGMDR1 patients also present general dystrophic features, such as necrotic
areas with regenerative regions, fiber size variability, central nuclei, and disorganized myofibrils
(Figure 3). Finally, muscles from LGMDR1 patients may present myonuclear apoptosis and a peculiar
pattern of focal degeneration, as well as fibers with a lobulated pattern, commonly attributed to
sarcomere and mitochondria disorganization [50].
3. CAPN3 Localization and Function
CAPN3 belongs to the calpain superfa ily of Ca2+-dependent non-lysosomal cysteine proteases.
Calpains have relevant functions in a y cell lar rocesses, including cell motility, a optosis, cell
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differentiation, and cell-cycle regulation. In these processes, intracellular Ca2+ activates calpains, which
then cleave specific substrates [77–80]. In mammals, the ubiquitous CAPN1 (µ-calpain) and CAPN2
(m-calpain) are the most extensively studied calpains. CAPN3 shares catalytic domain structure with
CAPN1 and CAPN2 but CAPN3 has three unique regions, namely NS, IS1, and IS2, (Figure 4) that
confer this protein some unusual features, such as an extreme instability and fast autodegradation rate,
and a Na+-dependent activation [81].
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Figure 4. Schematic representation of CAPN3 structure. CAPN3 is comprised of two protease core
domains (PC1 and PC2), a calpain-type β-sandwich domain (CBSW), and a penta E-F hand domain
(PEF) that binds four calcium ions and may contribute to CAPN3 dimerization. The three specific
regions of CAPN3 (NS, IS1, and IS2) are shown in blue. Schematics have been modified from Ye et al.,
2018 [82]. The right panel depicts the estimated tertiary structure of CAPN3.
One of the most remarkable features of CAPN3 is its extreme autodegradation rate [83], which
has hindered conventional biochemical analysis. Indeed, the native structure of CAPN3 remains
unresolved, as well as the accurate interactions of CAPN3 with other proteins. Another extremely
unusual characteristic of CAPN3 is its ability to regain proteolytic function after its autolytic dissociation.
This occurs through iMOC, a process where two autolytic fragments of CAPN3 reconstitute an active
core protease domain [84]. With regards to its proteolytic function, CAPN3 can be activated at
physiological intracellular concentrations of Ca2+ (100 nM) and Na+ (15 mM) [85], and thus, Na+ is
responsible for the low Ca2+ levels required to activate CAPN3. In fact, in absence of Na+, the Ca2+
concentration required for CAPN3 autolysis would be around 0.1 mM. Hence, in the skeletal muscle,
CAPN3 autolytic activity is suppressed in viv , th ugh its bi ding to connectin/titin [86]. CAPN3
pres s both proteolytic as well as on-proteolytic func i ns [81]. Different studi s ave identified
several mechanisms dependent on CAPN3 prot olyt c function, such as mechanosensory transduction
and sarcomere remodeling after exercise [81,87]. Non-prote lytic features of CAPN3, independent
of its protease activity, have been identified through comparative studies in CAPN3 knockout and
knock-in mice. These studies indicate that CAPN3 contributes to the maintenance of Ca2+ homeostasis
through the stabilization of critical Ca2+-handling proteins, which relies on non-proteolytic functions
of CAPN3 [88–90]. These functions will be further discussed in the following section.
CAPN3 presents a broad distribution within the muscle fiber, having been found at the sarcomere,
membrane fraction, sarcoplasmic reticulum (SR), cytosol, and even the nucleus [88,91,92]. CAPN3
has been mainly implicated in the regulation of muscle contraction and sarcomere stability [85,92–94].
Within the sarcomere, CAPN3 is localized in several regions, where it interacts with different proteins.
CAPN3 interacts at the Z-line with α-actinin-3, tropomyosin, and LIM-domain binding protein 3.
CAPN3 also interacts with titin, a large scaffold protein that plays a vital role in sarcomere assembly
and passive tension of myofibrils, as well as in mechanosensory transduction pathways [92,95].
Interestingly, CAPN3 binds to titin at the N2A and M-line regions, with different affinity depending on
the sarcomere length. Thus, the pres nce of CAPN3 at the N2A region is increased compared to the
M-lin gion when the sarcomere stretches. This loca i n shift along different titin regions is facilitated
by CAPN3 pr teolytic activity [93], and it is crucial for the dissociatio of Muscle Ankyrin Repeat
Protein-2 (MARP-2) from titin, and its translocation to the nucleus to transmit signals of mechanical
perturbation [96], which suggests that CAPN3 may function as a sensor of sarcomere integrity.
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Titin stabilizes CAPN3 by preventing its autodegradation [69], and therefore, CAPN3 activity
may be regulated by titin binding. On the other hand, since titin is also a CAPN3 substrate, CAPN3
may be responsible for the fast turnover of titin [97], and likely other sarcomere proteins, an aspect
that is necessary for appropriate maintenance of the sarcomere structure [98,99]. In this line, C3KO
mice present abnormal A-bands at the sarcomere and delayed myofibrillogenesis [69], together with
an accumulation of high molecular weight ubiquitin-protein conjugates [87]. Altogether these findings
suggest that proper interaction between CAPN3 and titin is essential for sarcomere maintenance and
remodeling [100].
4. Ca2+-Mediated Pathogenic Mechanisms Involved in CAPN3 Deficiency
Evidence obtained from animal models and human patients implicates Ca2+ homeostasis as a
pathophysiological mechanism underlying different muscular dystrophies, including LGMDR1 [5].
Several mouse models of LGMDR1 have been used to understand the pathogenic mechanisms resulting
from CAPN3 deficiency. Among these models, the CAPN3 knockout mouse lines Capn3−/− and
C3KO [69,101], and the CAPN3 knock-in mice Capn3CS/CS, expressing a structurally intact but inactive
CAPN3 [96,102] have enabled to identify specifically non-proteolytic and proteolytic functions of
CAPN3. Noteworthy, the phenotype of these mouse models does not fully recapitulate the severity of
LGMDR1 in human patients, likely due to the higher regenerative potential of the murine muscle [103]
and/or the increased Ca2+ buffering capacity of murine fibers [67]. Therefore, data from cellular
models and muscle samples of patients with LGMDR1 need to be considered in order to unravel the
molecular pathways involved in LGMDR1. During the last years, our group has been working on
understanding these mechanisms using human biopsies as well as primary and immortalized human
myotubes [67,68,104]. Below, we will review recent findings on pathogenic mechanisms associated with
CAPN3 deficiency, with a particular focus on the involvement of Ca2+ dysregulation, as summarized
in Figure 5.
4.1. Calcium Dysregulation
CAPN3 has been found to interact with several key Ca2+-handling proteins, such as RyR1, CSQ,
and SERCA [88]. In this line, several studies have shown that CAPN3 deficiency results in abnormal
Ca2+ handling in the skeletal muscle. Indeed, previous studies performed on the CAPN3 knockout
mice C3KO and Capn3−/−, indicate that these mice present reduced RyR1 expression together with a
decrease in SR Ca2+ release [89,90]. Also, Capn3−/− knockout myotubes display reduced SR Ca2+ levels
together with a lower response to SERCA inhibitors compared to wild-type myotubes [90]. Moreover,
we have also contributed to a study showing reduced RyR1 expression and CaMKII signaling in
muscles from LGMDR1 patients and C3KO mice [73]. At the triads, CAPN3 is part of a complex
comprised of RyR1, AldoA, and CaMKII. Interestingly, in the absence of CAPN3, in C3KO mice, both
RyR1 and CaMKII protein levels are decreased while AldoA is mislocalized. Thus, CAPN3 has been
proposed as a structural stabilizer of RyR1 complexes at the triads [73,89]. This structural function
of CAPN3 may depend on specific genetic regions since a recent study with LGMDR1 patients has
reported a new CAPN3 mutation that does not result in diminished RyR1 in the skeletal muscle [70].
Our group has recently found that mouse and human myotubes deficient for CAPN3 display
decreased SERCA protein levels as well as impaired Ca2+ reuptake into the SR [67,68]. Moreover,
we also found reduced SERCA expression in muscle samples from LGMDR1 patients. In line with
these findings, a recent study has shown that in sporadic inclusion body myositis, a common acquired
muscle disease associated with aging, there is a secondary calpainopathy and a concomitant reduction
of SERCA proteins that leads to Ca2+ dyshomeostasis [105]. Interestingly, we have found that SERCA
deficiency in CAPN3 knockdown myotubes resulted in increased resting intracellular [Ca2+] in human
myotubes, but not in mouse myotubes [67]. This is likely due to the fact that mouse muscle fibers have
a higher Ca2+ buffer capacity, since parvalbumin, a major cytosolic Ca2+ buffer, is highly expressed
in the mouse muscle [68]. In any case, SERCA mRNA levels were found unchanged in CAPN3
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deficient samples, and therefore, we propose that CAPN3 is necessary to stabilize SERCA proteins and
prevent their degradation, similarly to RyR1 and CaMKII. Interestingly, impaired SERCA function
leads to SR Ca2+ depletion and ultimately to SR stress that activates the unfolded protein response
(UPR) [106,107]. Indeed, in CAPN3 deficient myotubes, we found that several makers of SR stress and
UPR are upregulated such as GRP78, CHOP, HERP, and the XBP1 spliced variant [68].
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Figure 5. Schematic representation of putative Ca2+-mediated pathogenic mechanisms triggered by 
CAPN3 deficiency. CAPN3 deficiency results in reduced levels of RyR1, SERCA, and CaMKII. In 
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Figure 5. Schematic representation of putative Ca2+-mediated pathogenic mechanisms triggered
by CAPN3 deficiency. CAPN3 deficiency results in reduced levels of RyR1, SERCA, and CaMKII.
In addition, NCX3 activity may also be reduced. The decreased function of major Ca2+-handling
proteins results in Ca2+ dysregulation and incr as d intracellular [Ca2+]. Reduced CaMKII levels
together with Ca2+ dysregulation compromise CaMK downstream signaling pathways, which may lead
to impaired gene transcription, mitochondrial abnormalities, oxidative stress, altered fiber phenotype,
and impaired muscle regeneration. Mitochondrial abnormalities aggravate Ca2+ dysregulation and
oxidative damage. They may also impact energy production and promote apoptosis through Cyt-c
release and activation of caspases. Among these mechanisms, multiple feedback loops lead to altered
Ca2+ levels and may result in myoapoptosis and muscle waste. Black arrows or blunt ends indicate
enhancing or inhibitory effects, respectively. Red arrows indicate decreased protein expression. Text in
red boxes represent several pathological features of CAPN3, as described in Figure 2.
Finally, CAPN3 may also regulate Ca2+ homeostasis by increasing the activity of NCX3.
In HEK293T Michel et al. describe an increased activity of the NCX3 muscle isoform, NCX3-AC,
following CAPN3 cleavage [108]. This Na+/Ca2+ exchanger is found at the triads and extrudes Ca2+
across the sarcolemma to lower intracellular [Ca2+] during relaxation [108]. Nevertheless, more studies
need to be performed in order to verify the regulation of NCX3 by CAPN3 in myotubes as well as in
LGMDR1 models.
4.2. Abnormal Muscle Adaptation
The skeletal muscle is a remarkably adaptable tissue that responds to physiological and
environmental challenges by altering its size and composition [109]. Ca2+ plays a fundamental
role in muscle adaptation to changes in functional demand by activating specific Ca2+-dependent
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transcriptional pathways, such as CaMK pathways, in order to control muscle growth, fiber type
transition, or mitochondrial biogenesis. In particular, CaMKII has been proposed as a major sensor of
muscle activity that translates it into phenotypic adaptations by regulating the transcription of specific
genes [30]. CaMKII signaling has been found severely compromised in the CAPN3 knockout mice,
C3KO, and thus, abnormal muscle adaptation has been proposed as a major instrumental mechanism
in LGMDR1 [73,74]. Indeed, in C3KO mice, reduced CaMKII expression results in an impaired slow
myogenic program [73]. This may explain why muscles highly enriched in slow-twitch fibers, such
as soleus and diaphragm are the most severely affected in C3KO mice, and also why there seems
to be a preferential involvement of slow fibers in LGMDR1 muscle biopsies [73]. Moreover, after
endurance exercise, CAPN3 deficient muscles fail to upregulate several groups of genes associated
with muscle adaptation, such as myofibrillar, mitochondrial, and metabolic genes [74]. In this line, we
have observed that human myotubes deficient for CAPN3 show reduced protein levels of CaMKII
(unpublished data).
4.3. Mitochondrial Abnormalities
Several studies support the notion that CAPN3 is an important modulator of mitochondrial
function, and its absence seems to have major consequences over this organelle [72,110]. LGMDR1
patients and CAPN3 knockdown mice present abundant mitochondria with abnormal spatial
distribution [50,72,111], and a recent study points toward mutation-specific patterns of mitochondrial
dysfunction in different LGMDR1 patients [70]. Moreover, in C3KO mice, mitochondria display a
swollen appearance with disrupted membranes [72], while in LGMDR1 muscle biopsies, several
mitochondrial genes have been found to be deregulated [112]. Mitochondrial abnormalities would
have a direct impact on several pathomechanisms in LGMDR1, including Ca2+ dysregulation, energy
deficits, oxidative stress, and ultimately, they could lead to cell death through the release of different
pro-apoptotic factors into the cytosol (Figure 3). Indeed, C3KO muscles present decreased ATP
production and increased oxidative stress [72], while LGMDR1 muscles show Cyt-c mislocalization to
the cytosol [91], which may promote activation of caspases and apoptosis [113]. Likewise, mitochondria
biogenesis and function are severely affected by Ca2+ dyshomeostasis [5]. Thus, while Ca2+ promotes
mitochondrial metabolism and ATP synthesis, sustained high intracellular Ca2+ levels, such as the ones
found in CAPN3 deficient myotubes [67,68], may result in mitochondrial Ca2+ overload and eventually
lead to mitochondrial dysfunction and muscle cell degeneration. On the other hand, mitochondria
biogenesis is modulated by PGC1α, which is in turn regulated by Cn and CaMK pathway, and therefore
it is highly susceptible to Ca2+ dysregulation [40,114]. In this line, during muscle regeneration, CAPN3
knockout mice have proved unable to increase mitochondrial DNA content, as well as PGC1α and
ATP5D transcripts, likely due to diminished CaMKII signaling [71].
4.4. Oxidative Stress
Oxidative and nitrosative stress have been associated with muscle wasting in several muscular
dystrophies, including LGMDR1, where NAPDH oxidase appears to be one potential source of oxidative
stress in LGMDR1 muscle biopsies [65]. In LGMDR1 biopsies, elevated reactive oxygen species (ROS),
increased oxidized proteins, and lipid peroxidation have been reported [65,66]. Oxidative stress has also
been associated with C3KO mouse muscles [72], where defective mitochondria may be a contributing
factor since they are considered to generate the majority of cellular free radicals. Reciprocally, oxidative
stress may also lead to mitochondrial damage [115], as well as Ca2+ dysregulation [116]. Therefore,
identification of the cause-effect relationship among these features is very challenging. In any case,
oxidative stress can cause cell death through necrotic or apoptotic pathways.
In response to oxidative stress, several protective mechanisms are activated to buffer extra ROS,
such as superoxide dismutases (SOD). An increment in their concentration is indicative of oxidative
stress. Accordingly, in CAPN3 knockout mouse increased levels of SOD have been reported, indicating a
suitable protective response against oxidative stress [66]. In contrast, a reduction of antioxidant defense
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mechanisms has been described in LGMDR1 biopsies [66], pointing toward a higher vulnerability of
human LGMDR1 muscles compared to mouse C3KO muscles.
4.5. Impaired Muscle Regeneration
Impaired muscle regeneration is another main pathological feature of LGMDR1 [71]. Muscle
regeneration is a complex process that is initiated upon injury of muscle cells and can be divided
into several stages: activation and proliferation of satellite cells, which are the muscle stem cells,
differentiation or fusion of the muscle stem cells, maturation of the newly formed muscle fibers and
the remodeling of muscle fibers. This process requires high levels of protein synthesis, proper mRNA
translation, and energy consumption. Different signaling pathways underlie these processes, such as
AMP-activated protein kinase (AMPK) signaling, which is regulated by CaMKII and liver kinase B1
(LKB1) [117,118]. In C3KO mice, during muscle regeneration after CTX injection, muscle fiber growth
is arrested due to increased AMPK phosphorylation, inhibition of mTORC1, and energy shortage [71].
Regeneration is one of the most energy-consuming cellular processes, and therefore, C3KO mice fibers
are not able to activate genes necessary to adapt to a new situation [119,120]. Moreover, abnormal
sarcomere organization in C3KO mice may also contribute to impaired muscle regeneration [69].
Interestingly, in regenerating C3KO muscles [71], as well as in LGMDR1 biopsies [121], a
similar miRNA pattern has been reported to the one described in muscles with impaired myofiber
repair/regeneration and subsequent fibrosis, showing increased Pax7 expression and downregulation of
the muscle specific miRNAs miR-1, miR-133a, and miR-206. These miRNAs, also known as dystromirs,
are involved in myogenesis by promoting muscle proliferation (miR-133a) and differentiation (miR-1
and miR-206) [122]. Downregulation or inhibition of miR-1 and miR-206 is associated to increase in the
proliferation of satellite cells and Pax7 expression in vivo [123,124]. On the other hand, miR-133a is
involved in the maintenance of adult skeletal muscle structure, function, bioenergetics and myofiber
identity [125]. Remarkably, mir-1, miR-206, and miR-133a have been proposed as disease biomarkers
for Duchenne muscular dystrophy [122].
Finally, MyoD modulation by CAPN3 has been demonstrated in murine cell cultures, which
signals CAPN3 as a potential player during muscle regeneration [126]. Moreover, a defective fusion
of C3KO myoblast has been described in vitro, due to an accumulation of the β-catenin-M-cadherin
complex at the membrane [127]. CAPN3 regulates the localization of β-catenin [127]. At the same
time, FRZB, through the inhibition of the Wnt pathway, may prevent the translocation of β-catenin to
the nucleus [104]. Interestingly, upregulated FRZB expression has been found in LGMDR1 muscle
samples [104]. Therefore, CAPN3 seems to be involved in the fusion and maturation processes of
myogenic cells.
4.6. Myoapoptosis
Several studies have reported apoptotic myonuclei in muscle samples from LGMDR1 patients [91]
and Capn3−/− CAPN3 knockout mice [101]. Conversely, similar studies performed in the C3KO mice
fail to detect apoptotic nuclei in muscle fibers [69]. Differences in Ca2+ buffer capacity or protective
response against oxidative stress may account for the lack of apoptotic nuclei in this mouse model
of LGMDR1.
In LGMDR1, apoptosis may be triggered through several pathways (see Figure 5). First, CAPN3
activates NFκB in a Ca2+ dependent manner, through degradation of the NF-κB inhibitor IκBα [101].
Activation of NF-κB in the skeletal muscle may lead to protein degradation, inflammation, and
fibrosis [128], but it also may promote muscle cell survival under certain conditions [129,130].
This seems to be the case in LGMDR1 since previous works have shown that CAPN3 regulates
the expression of NF-κB-dependent survival genes to prevent apoptosis in skeletal muscle, such as
c-FLIP [129]. In particular, the expression of c-FLIP, a master anti-apoptotic regulator downstream
NF-κB signaling pathway, is downregulated in human myotubes and mouse muscle deficient for
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CAPN3 [68]. Deregulations in the NF-κB pathway could be part of the mechanism responsible for the
muscle wasting resulting from CAPN3 deficiency.
On the other hand, Cn also plays a significant role in apoptosis through the dephosphorylation of
proteins involved in the apoptotic pathway, such as caspase 9. Phosphorylation of caspase 9 by Akt
pathway results in caspase 9 inhibition, while Cn triggers caspase activity via dephosphorylation [131].
Third, Cyt-c leakage from mitochondria promotes apoptosome generation in the cytosol, which
activates caspase 9 and the downstream caspase cascade, and may result in myoapoptosis [113].
Interestingly, a cytosolic Cyt-c localization has been reported in LGMD2A muscle biopsies [91].
Lastly, sustained SR stress, elevated intracellular calcium, and oxidative stress, all of which
underlie LGMDR1 pathology, may also lead to apoptosis through caspase activation. Therefore,
further studies are needed to elucidate the molecular mechanisms that trigger the apoptotic pathway
and muscle waste in LGMDR1. These findings may be highly valuable for identification of novel
therapeutic candidates.
5. Therapeutic Approaches for LGMDR1
Similar to other hereditary disorders, there are currently no effective therapies to treat LGMD.
Moreover, treatments for these diseases have mostly been symptomatic so far. However, new treatments,
both non-disease- and disease-specific, are emerging for LGMD [132]. Among non-disease-specific
treatments, both strength and aerobic exercise training are beneficial for LGMD. In particular, strength
training improves strength in LGMDR1, although improvement generally seems smaller than with
endurance training [133,134]. One proposed pharmacological approach is to increase muscle mass by
enhancing positive regulators of muscle growth, or by inhibiting negative regulators, such as myostatin.
In this regard, in the Capn3−/− mouse model of LGMDR1, treatment with AAV-carrying a mutant
myostatin propeptide with an inactive C-terminal domain has shown increased muscle mass and
improved force generation [135]. On the other hand, a Phase I/II trial with MYO-029, a recombinant
human antibody that inhibits myostatin activity has shown good tolerability but minimal improvement
in the muscle strength and the pathology of patients with LGMD [136].
Table 1. Therapeutic strategies for limb-girdle muscular dystrophy recessive 1 (LGMDR1).
Therapy Clinical-PharmacologicalUse State Comments Ref.
Pharmacological
Therapy
MYO-029
Myostatin human
recombinant neutralizing
antibody
Competed I/II trial Minimal improvement inmuscle strength [136]
Gene therapy
AAV-delivered mutant
myostatin propeptide
Prevention of the cleavage of
myostatin propeptide Preclinical
Increased muscle mass and
force generation in mice [135]
AAV-mediated transfer
of calpain 3
Increase of calpain 3
expression and function Preclinical
Rescue of the contractile
force deficits in mice [137]
Plasmid DNA Increase of calpain 3expression and function Active project [138]
AAVrh74 vector Increase of calpain 3expression and function Active project Systemic delivery to muscle [139]
Cell therapy
iPSC Increase of calpain 3expression and function Active project [140]
Although a meaningful effort has been made in all these areas to address the challenge of
developing therapies for LGMDR1, to date, most groups are focused on correcting the primary genetic
defect through the use of adeno-associated virus (AAV) gene therapy, transcriptional modification
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approaches (exon skipping and induction of stop codon read-through) or cell therapy (stem cells and
induced pluripotent stem cells) [141]. In the particular case of LGMDR1, there are currently few ongoing
therapeutic approaches, and so far, they are only showing a moderate efficacy. Therefore, there is a need
for developing new therapeutic strategies directed toward alternative targets of the disease, such as the
ones summarized in Figure 2. To date, in the LGMDR1 mouse model, transfer of the AAV-mediated
CAPN3 gene has shown safety and efficacy, resulting in significant myopathology amelioration [137].
Moreover, gene correction in LGMDR1 patient-specific iPS cells has been successfully achieved. Those
genetically corrected iPS cells might be evaluated in vitro and in vivo once differentiated into skeletal
muscle progenitors, in order to address the efficient restoration of full-length CAPN3 [140]. Finally,
Sarepta, in association with Nationwide Children’s Hospital, has recently announced a gene therapy
program using the AAVrh74 vector, designed to replace CAPN3 in the skeletal muscle via systemic
administration. AAVrh74 has a robust affinity for muscle cells, with a relatively low level of pre-existing
immunity [142]. This vector has been previously used in other gene therapy programs targeting
Duchenne Muscular Dystrophy and five other LGMDs [143,144]. All the therapeutic approaches for
LGMDR1 described above are summarized in Table 1.
6. Future Directions and Conclusions
The role of Ca2+ dysregulation as a pathological mechanism underlying LGMDR1 is increasingly
becoming accepted. Here, we have reviewed different participants disrupted in LGMDR1 that
regulate Ca2+ homeostasis. Several of these Ca2+-handling proteins may be interesting candidates
for therapeutic approaches for calpainopathies. In this line, treatment with RyR stabilizers has
shown an improvement of muscle function in mouse models of Duchenne and LGMDR4 muscular
dystrophies [116,145]. Thus, it would be interesting to test these compounds as well as other therapeutic
approaches targeting Ca2+-handling proteins compromised in LGMDR1 such as CaMKII and SERCAs.
SERCA overexpression could be achieved through AAV-mediated gene therapy [146,147], but several
drugs may also prove useful in increasing SERCA expression or function, including adrenoreceptor
blockers, adrenergic agonists, hormones, glucocorticoids, natural antioxidants, and small molecule
SERCA activators such as CDN1163 [58,148,149]. Alternatively, reduction or down-regulation of SERCA
inhibitors SLN [150] and PLN [151] could be considered. Finally, inhibition of SERCA degradation
through the ubiquitin-proteasome system has been shown to rescue SERCA1 function in a cellular
model of Brody disease [152], and therefore, it might also have therapeutic potential for LGMDR1.
Several therapeutic approaches targeting mitochondrial dysfunction and oxidative stress have
been shown to improve muscle function in different dystrophic mouse models and could therefore
also be effective in ameliorating LGMDR1 phenotype. These therapies include cyclosporine A and
cyclophilin D inhibitors (Debio 025) targeting mitochondrial PTP opening, pargyline for the excessive
accumulation of reactive oxygen species and overexpression of PGC1α for mitochondrial dysfunction
in post-necrotic dystrophic muscles [153].
While genetic correction of CAPN3 is so far one of the most promising therapeutic approaches
aiming to cure LGMDR1, there is still much work to be done before gene therapy is available for these
patients. Indeed, these therapies need to overcome several hindrances in LGMDR1 patients, including
potential immune response resulting from AAV or CAPN3 introduction, as well as efficient delivery of
viral vectors to affected muscles without off-target effects. Moreover, it should be taken into account that
not every LGMDR1 patient may qualify for this kind of therapy. In this context, therapeutic approaches
targeting key Ca2+-handling proteins in LGMDR1 may help ameliorate dystrophic progression in
LGMDR1, since, as discussed in this review, Ca2+ dysregulation seems to play a central pathogenic role
in this disease. In any case, further studies of the different pathogenic mechanisms underlying LGMDR1
are essential for helping us understand the many elusive functions of CAPN3 in the skeletal muscle.
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AAV Adeno-associated virus
Akt Protein kinase B
AldoA Aldolase isoform A
AMP Adenosine monophosphate
AMPK AMP-activated protein kinase
ATP Adenosine triphosphate
ATP5D ATP synthase subunit delta
C3KO Calpain 3 knockout mouse
CaM Calmodulin
CAMK Ca2+/calmodulin-dependent protein kinase family
CAMKII Ca2+/calmodulin-dependent protein kinase type II
CAPN1 Calpain 1
CAPN2 Calpain 2
CAPN3 Human calpain 3 gene
CAPN3 Human calpain 3 protein
Capn3−/− Calpain 3 knockout mouse
CBSW Calpain-type beta-sandwich
c-FLIP Cellular FLICE inhibitory protein
CK Creatine Kinase
Cn Calcineurin
CSQ Calsequestrin
CTX Cardiotoxin
Cyt-c Cytochrome C
DHPR Dihydropyridine receptor
ECC Excitation-contraction coupling
FRZB Frizzled Related Protein
HDAC Class II histone deacetylases
IκBα Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, isoform alpha
iMOC Intermolecular complementation
iPSC Induced pluripotent stem cell
IS1 Insertion sequence 1
IS2 Insertion sequence 2
LGMD Limb girdle muscular dystrophy
LGMD2A Limb girdle muscular dystrophy type 2A, renamed LGMDR1
LGMD2B Limb girdle muscular dystrophy type 2B, renamed LGMDR2
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LGMDD4 Limb girdle muscular dystrophy dominant 4
LGMDR1 Limb girdle muscular dystrophy recessive 1, caused by mutations in CAPN3
LGMDR2 Limb girdle muscular dystrophy recessive 2, caused by mutations in dysferlin
LGMDR4 Limb girdle muscular dystrophy recessive 4, caused by mutations in β-sarcoglycan
LKB1 Liver kinase B1
MAM Mitochondria-associated sarcoplasmic reticulum membrane
MARP-2 Muscle Ankyrin Repeat Protein-2
MEF2 Myocyte enhancer factor-2
miRNA Micro ribonucleic acid
mRNA Messenger ribonucleic acid
mTOR Mammalian target of rapamycin
mTORC1 Mammalian target of rapamycin complex 1
MyoD Myoblast determination protein 1
NCX Na+/Ca2+ exchanger
NCX3 Na+/Ca2+ exchanger isoform 3
NFAT Nuclear factor of activated T-cells
NF-κB Nuclear factor kappa-ligjht-chain-enhancer of activated B cells
NS N-terminal addition sequence
Pax7 Paired box protein 7
PC1 Protease core subdomain 1
PC2 Protease core subdomain 2
PEF Penta E-F hand
PGC1α Peroxisome proliferator activated receptor gamma coactivator 1 alpha
PKA Protein kinase A
PLN Phospholamban
PMCA Plasma membrane calcium ATPase
PTP Permeability Transient Pore
ROS Reactive oxygen species
RyR Ryanodine receptor
RyR1 Ryanodine receptor isoform 1
SERCA Sarco/endoplasmic reticulum Ca2+-ATPase
SERCA1 Sarco/endoplasmic reticulum Ca2+-ATPase isoform 1
SERCA2a Sarco/endoplasmic reticulum Ca2+-ATPase isoform 2a
SLN Sarcolipin
SOD Superoxide dismutase
SR Sarcoplasmic reticulum
T-tubule Transverse tubule
UPR Unfolded protein rsponse
Wnt Wingless-related integration site
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